Binding molecules for FRα

JP2025508009A5Pending Publication Date: 2026-03-06ASTRAZENECA AB
0 Cites 0 Cited by

Patent Information

Application Number
JP2024552760
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-03-09
Filing Date
2023-03-01
Publication Date
2026-03-06

AI Technical Summary

Technical Problem

Existing FRα-targeted antibody drug conjugates (ADCs) have problems with low efficiency, high toxicity and insufficient antibody internalization when delivering cytotoxic agents, and complex structures increase manufacturing costs and immunogenicity.

Method used

Develop a new antibody drug conjugate, which uses specific anti-FRα single antibody or its antigen-binding fragments to bind highly effective cytotoxic agents, such as topoisomerase I inhibitors, to improve the targeting efficiency and safety of drugs by optimizing the antibody structure and ligation mode.

Benefits of technology

Efficient delivery of cytotoxic agents to target cells is achieved, significantly improving killing efficacy against tumor cells, while reducing toxicity to patients, simplifying the manufacturing process and reducing costs.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure provides binding molecules (e.g., antibodies or antigen-binding fragments thereof) and related antibody-drug conjugates to FRa, as well as pharmaceutical compositions and kits comprising the same. Methods of using the binding molecules and related antibody-drug conjugates in the treatment of cancer are also provided.
Need to check novelty before this filing date? Find Prior Art